Leaderboard
Anzeige
medline.ch
En
|
De
Impressum
No articles selected!
View Cart
You are here:
Oncology
»
Urologic Neoplasms
18. July 2026
Search
medline.ch
Urologic Neoplasms
Advanced search
Dermatology
Endocrinology
Nutrition
Gastroenterology
Gynecology
Haematology
Infectious diseases
Cardiovascular Diseases
Musculoskeletal Diseases
Neurology
Oncology
Musculoskeletal System
Blood
Endocrine System
Gynecologic Neoplasms
Skin
Gastrointestinal
ORL
Respiratory Tract
Urologic Neoplasms
CNS
ORL
Pediatrics
Psychiatry
Respiratory Tract
Sports
Urology-Nephrology
Rect Top
Anzeige
Zoom:
Page 1 of 9007
Articles 1 - 20 / 180137
Emerging antibody-drug conjugates in metastatic castration-resistant prostate cancer.
Urol Oncol
Nguyen CB, Reichert ZR.
PMID: 42469055 [PubMed - as supplied by publisher]
Reply to Antonio Cigliola, Andrea Necchi, and Umberto Capitanio's Letter to the Editor Re: Metastasis-directed Therapy with or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.024.
Eur Urol
Sherry AD, To V, Msaouel P, Neeson P, Tang C, Siva S.
PMID: 42469054 [PubMed - as supplied by publisher]
Artificial Intelligence in Digital Pathology for Prostate Cancer Detection: FDA Clearance and Real-World Implementation.
J Clin Pathol
Rainer Q, Sun Y, Vyas M, Kopach P, Gondim D, Muthukumarana V, Thaker H, Deshpande V.
PMID: 42468971 [PubMed - as supplied by publisher]
Radiation-induced erectile dysfunction in prostate cancer: A systematic review of pathophysiology, clinical radiobiology, and predictive modeling.
Phys Med
Saraei P, Bagheri A, Danyaei A, Jafari M, Salek R, Hosseini S, Obeidavi I, Chegeni N.
PMID: 42468493 [PubMed - as supplied by publisher]
Prognostic role of the Glasgow prognostic score and modified Glasgow prognostic score in patients with renal cell carcinoma undergoing immunotherapy: a meta-analysis.
Clinics (Sao Paulo)
Zhang X, Li X, Xie Y, Shi N.
PMID: 42468376 [PubMed - as supplied by publisher]
Patient-Reported Outcome Design and Analysis in Randomized Controlled Trials of Renal Cell Carcinoma: A Systematic Review.
Clin Genitourin Cancer
Chen D, Chen S, Sun D, Chow E, Lee SF, Wong HCY, Raman S.
PMID: 42468185 [PubMed - as supplied by publisher]
Automated volumetric iRECIST-inspired CT assessment of treatment response to dual immune checkpoint inhibition in metastatic renal cell carcinoma: A feasibility study.
Eur J Radiol
Kraaijveld RCJ, Ma B, Suelmann BBM, Wessels FJ, Ragusi MAA, de Keizer B, Gilhuijs KGA.
PMID: 42468161 [PubMed - as supplied by publisher]
Occupational exposure to metals and prostate cancer: CAPLIFE study.
Cancer Epidemiol
Olmedo-Requena R, Villanueva-Piqueras PJ, Lozano-Lorca M, Castillo-Hermoso MÁ, Jiménez-Moleón JJ, Salcedo-Bellido I.
PMID: 42468082 [PubMed - as supplied by publisher]
A Phase 2 Trial of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) for the Treatment of Non-Muscle Invasive BCG Unresponsive Urothelial Carcinoma of the Bladder.
J Urol
DeCastro GJ, Joffe BI, Stein MN, Abate-Shen C, Miles CH, Gray JM, Anderson CB, Lenis AT, McKiernan JM.
PMID: 42467648 [PubMed - as supplied by publisher]
Real-World Use of Prolaris® to Guide Treatment Decisions in Localized Prostate Cancer Eligible for Active Surveillance.
Urol Int
Melchior F, Koett M, Aigner G, Schroffenegger J, Weiss B, Ormanns S, Heidegger I.
PMID: 42467602 [PubMed - as supplied by publisher]
Neoadjuvant therapies for clear cell renal cell carcinoma: review of current evidence and future applications.
World J Urol
McMaster T, McVeigh N, Chen DC, Al-Khanaty A, Sandhu K, Carll J, Woon DT, Murphy DG, Lawrentschuck N, Au L, Ali M, Siva S, Perera M.
PMID: 42467100 [PubMed - indexed for MEDLINE]
A Nationwide Descriptive Analysis of Real-World Outcomes After Radical Prostatectomy in Japan Using the National Clinical Database.
Int J Urol
Sakamoto S, Yamamoto K, Yamamoto H, Hatakeyama S, Mizuno R, Yasui T, Kamoto T, Kikuchi E, Ito A, Kume H.
PMID: 42466819 [PubMed - indexed for MEDLINE]
Machine Learning Classification of Prostate Cancer Genomic Sequences Using K-Mer and Sequence-Derived Features.
Comput Mol Biosci
Rawat K, Banerjee HN, Noble J, Deloatch SN, Banerjee S, Shetty S, Banerjee S.
PMID: 42466157 [PubMed]
Correction to an immunometabolism-related signature for renal clear cell carcinoma diagnosis and therapeutic target.
J Cell Commun Signal
PMID: 42465982 [PubMed]
Tumor heterogeneity on contrast-enhanced computed tomography outperforms attenuation ratio in differentiating renal cell carcinoma subtypes: a pathologic correlation study.
Pan Afr Med J
Araminta ADE, Atmaja MHS, Ferriastuti W.
PMID: 42465830 [PubMed - indexed for MEDLINE]
The diagnostic value of biparametric magnetic resonance imaging vesical imaging-reporting and data system combined with tumor contact length for assessing muscle invasion in bladder cancer lesions scored vesical imaging-reporting and data system 3: A single-center retrospective analysis.
Indian J Urol
Bao W, Liu Y, Yang J, Ma X.
PMID: 42465796 [PubMed]
The immunotherapy paradox in high-risk non-muscle-invasive bladder cancer: A tale of three trials.
Indian J Urol
Agrawal S, Pal AK, Sharma S, Tanwar R, Sharma G.
PMID: 42465794 [PubMed]
The HERCULES trial and the emerging role of chemoimmunotherapy in advanced penile squamous cell carcinoma: Evidence and implications.
Indian J Urol
Pal AK.
PMID: 42465786 [PubMed]
The Evidence-Practice Gap in Testosterone Therapy for Prostate Cancer: A Narrative Review.
Cureus
Aly M, Joseph A, Amer T.
PMID: 42465160 [PubMed]
Prostate Cancer Screening: Current Controversies and Future Directions.
Cureus
Buali HF, Al Shaibani A, Farouqi US, Abushloa T, Bastawisy A, Aljeeran N, Albenjasim K, Rafie M.
PMID: 42465149 [PubMed]
Articles 1 - 20 / 180137
Page 1 of 9007
Rect Bottom
Anzeige
Adserver Footer
Time frame
--unlimited--
1 Week
1 Month
3 Months
6 Months
1 Year
2 Years
3 Years
5 Years
10 Years
Sky right 1
Anzeige
Mediscope AG E-mail:
info@mediscope.ch
Disclaimer
|
Privacy Policy